DYAI vs. ZNTL, SLN, CMPX, SOPH, MGNX, MOLN, GOSS, OGI, MDWD, and FATE
Should you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include Zentalis Pharmaceuticals (ZNTL), Silence Therapeutics (SLN), Compass Therapeutics (CMPX), SOPHiA GENETICS (SOPH), MacroGenics (MGNX), Molecular Partners (MOLN), Gossamer Bio (GOSS), Organigram (OGI), MediWound (MDWD), and Fate Therapeutics (FATE). These companies are all part of the "pharmaceutical products" industry.
Dyadic International vs.
Dyadic International (NASDAQ:DYAI) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.
Dyadic International received 102 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. Likewise, 64.40% of users gave Dyadic International an outperform vote while only 63.44% of users gave Zentalis Pharmaceuticals an outperform vote.
28.0% of Dyadic International shares are owned by institutional investors. 28.8% of Dyadic International shares are owned by insiders. Comparatively, 3.6% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Zentalis Pharmaceuticals has a net margin of 0.00% compared to Dyadic International's net margin of -188.09%. Zentalis Pharmaceuticals' return on equity of -43.91% beat Dyadic International's return on equity.
Dyadic International presently has a consensus target price of $6.00, indicating a potential upside of 222.58%. Zentalis Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 210.56%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts clearly believe Dyadic International is more favorable than Zentalis Pharmaceuticals.
Dyadic International has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Dyadic International is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Dyadic International has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500.
In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Dyadic International. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 3 mentions for Dyadic International. Zentalis Pharmaceuticals' average media sentiment score of 0.73 beat Dyadic International's score of 0.67 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.
Summary
Dyadic International and Zentalis Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Dyadic International News Delivered to You Automatically
Sign up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dyadic International Competitors List
Related Companies and Tools
This page (NASDAQ:DYAI) was last updated on 1/6/2025 by MarketBeat.com Staff
